- Intra-Cellular Therapies ( NASDAQ: ITCI ) is scheduled to announce Q4 earnings results on Wednesday, March 1st, before market open.
- The consensus EPS Estimate is -$0.59 (+43.8% Y/Y) and the consensus Revenue Estimate is $86.97M (+238.8% Y/Y).
- Over the last 1 year, ITCI has beaten EPS estimates 0% of the time and has beaten revenue estimates 100% of the time.
- Over the last 3 months, EPS estimates have seen 6 upward revisions and 1 downward. Revenue estimates have seen 6 upward revisions and 1 downward.
For further details see:
Intra-Cellular Therapies Q4 2022 Earnings Preview